Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, Inc. (NASDAQ:MAZE), filed a Form 4 on September 4, 2026, disclosing four sales of common stock on September 2 and September 3, 2026, all conducted to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Role: Courtney Phillips is identified as General Counsel and Corporate Secretary of Maze Therapeutics, Inc.
  • Transaction purpose: All shares sold were disposed of to satisfy tax withholding obligations upon the vesting of restricted stock units, according to the filing.
  • September 2 sales: 1,738 shares sold at a weighted average price of $26.376 per share, and 243 shares sold at a weighted average price of $27.1211 per share.
  • September 3 sales: 1,990 shares sold at a weighted average price of $26.0133 per share, and 22 shares sold at a price of $25.78 per share.
  • Remaining ownership: Following all four reported transactions, Phillips directly held 7,007 shares of Maze Therapeutics common stock, as reported in the filing.
  • Weighted average prices: Three of the four transactions involved multiple sub-transactions, with the filing noting price ranges and an undertaking to provide full detail upon request.

Phillips RSU Vesting Disposals at Maze Therapeutics in September 2026

According to the filing, each of the four disposals reported by Phillips bears transaction code "S" and is attributed in footnote 1 to shares sold specifically to cover tax withholding obligations arising from the vesting of restricted stock units. Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicine, and its officers are subject to standard Section 16 reporting requirements under the Securities Exchange Act of 1934.

For the September 2, 2026 transactions, the filing discloses that 1,738 shares were sold with prices ranging from $26.03 to $27.00 per share (weighted average $26.376), and 243 shares were sold with prices ranging from $27.055 to $27.40 per share (weighted average $27.1211). For the September 3, 2026 transactions, 1,990 shares were sold with prices ranging from $25.743 to $26.65 per share (weighted average $26.0133), and a separate lot of 22 shares was sold at $25.78 per share. The filing states that Phillips undertakes to provide full per-price detail upon request to the issuer, any security holder, or SEC staff.

After each successive transaction, the filing records the remaining direct beneficial ownership as follows: 9,262 shares after the first sale, 9,019 shares after the second, 7,029 shares after the third, and 7,007 shares after the fourth and final reported sale. No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

The filing reports four open-market disposals of Maze Therapeutics common stock by the company's General Counsel and Corporate Secretary between September 2 and September 3, 2026, all attributed to tax withholding upon RSU vesting, leaving a direct holding of 7,007 shares.